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ABSTRACT
Purpose To identify pharmacoepidemiological multi-database studies and to describe data management and data analysis techniques used
for combining data.
Methods Systematic literature searches were conducted in PubMed and Embase complemented by a manual literature search. We included
pharmacoepidemiological multi-database studies published from 2007 onwards that combined data for a pre-planned common analysis or
quantitative synthesis. Information was retrieved about study characteristics, methods used for individual-level analyses and meta-
analyses, data management and motivations for performing the study.
Results We found 3083 articles by the systematic searches and an additional 176 by the manual search. After full-text screening of 75 articles, 22
were selected for ﬁnal inclusion. The number of databases used per study ranged from 2 to 17 (median=4.0). Most studies used a cohort design
(82%) instead of a case–control design (18%). Logistic regression was most often used for individual-level analyses (41%), followed by Cox regres-
sion (23%) and Poisson regression (14%). As meta-analysis method, a majority of the studies combined individual patient data (73%). Six studies
performed an aggregate meta-analysis (27%), while a semi-aggregate approach was applied in three studies (14%). Information on central program-
ming or heterogeneity assessment was missing in approximately half of the publications. Most studies were motivated by improving power (86%).
Conclusions Pharmacoepidemiological multi-database studies are a well-powered strategy to address safety issues and have increased
in popularity. To be able to correctly interpret the results of these studies, it is important to systematically report on database management
and analysis techniques, including central programming and heterogeneity testing. © 2015 The Authors. Pharmacoepidemiology and
Drug Safety published by John Wiley & Sons, Ltd.
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INTRODUCTION
The need for post-approval surveillance of drug safety
has been widely recognized for more than four decades.
From the early days of pharmacoepidemiology, initia-
tives have been undertaken to study safety and, most re-
cently, effectiveness of medications using routinely
collected healthcare data. Over the past decade, an
increasing number of studies have been performed using
healthcare databases from multiple countries, regions or
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healthcare organizations. Using data from multiple data-
bases offers a number of potential advantages such as in-
creased sample size (datasets become large enough to
give precise estimates of medication risks and beneﬁts
even for rare outcomes and exposures) and generaliz-
ability (when similar results are found in studies utilizing
the same methodology in heterogeneous populations).
Furthermore, it offers a potential for using a standard-
ized methodological approach across data sources.
A number of large initiatives have been launched to
develop methods for combining data from multiple
databases and registers. In the United States (U.S.),
the Observational Medical Outcomes Partnership
(OMOP)1 and the Mini-Sentinel program2 have been
run since 2007 and 2008, respectively. Data are often
combined using the health maintenance organization
(HMO) Research Network, a consortium of 19 large
healthcare delivery organizations in the U.S.3 The Ca-
nadian Network for Observational Drug Effect Studies
(CNODES), a distributed network of Canadian re-
searchers and data centers, was launched in 2011.4,5
European initiatives that address logistical and meth-
odological problems of conducting multi-database
studies include EU-ADR6 and IMI-PROTECT.7
Recently, the Asian Pharmacoepidemiology Network
(AsPEN),8 a collaboration including Asian countries,
was also started. Besides these large programs, a hand-
ful of smaller research projects have also combined data
from several healthcare databases.9–13
There are various ways to combine data from sev-
eral independent databases, which all have different
advantages and disadvantages. A combination of ag-
gregate results does not require sharing of individual
patient data and makes optimal use of locally available
data (e.g. information on confounders). However,
correcting for heterogeneity between the databases
may not be fully possible when combining summary
estimates. A combination of individual patient data
opens more space for exploring and correcting for het-
erogeneity; it offers an opportunity to use exactly the
same deﬁnitions of exposures, outcomes, covariates,
and time windows. This approach may, however, re-
sult in a compromise when relevant information is lost
if not available in all databases (possibly leading to
larger residual confounding).
To our knowledge, no systematic review has been
performed yet to select multi-database studies and to
illuminate which methods have most frequently been
used to combine data. Our aim was therefore to iden-
tify pharmacoepidemiological studies using a pre-
planned multi-database approach and to describe data
management and data analysis techniques used for
combining data.
METHODS
Literature search
We conducted systematic literature searches in
PubMed and Embase, as well as a manual literature
search, to identify relevant multi-database observa-
tional studies. We followed the PRISMA guideline
(www.prisma-statement.org).
The following inclusion criteria were applied: (i)
peer-reviewed pharmacoepidemiological study (de-
ﬁned as an observational study about the safety or ef-
fectiveness of medication); (ii) published from 2007
onwards; (iii) study subjects were selected from two
or more independent healthcare databases (i.e. data-
bases covering a different study population); (iv) all
databases within the study were analyzed to answer
the same research question; and (v) data were com-
bined for a pre-planned common analysis or quantita-
tive synthesis (i.e. data were combined either at
individual patient-level or the estimates obtained from
individual databases were combined in analyses). We
excluded drug utilization studies, articles that focused
on the detection of adverse drug reactions (ADRs)
and other pharmacovigilance studies, studies that only
reported results from separate databases without pro-
viding any combined estimates, purely methodological
papers (e.g. describing methods to combine data, but
not actually doing so in the paper), as well as studies
published in languages other than English (exclusion
criteria were applied sequentially).
Systematic search strategies for PubMed and
Embase were developed under the supervision of a re-
search librarian and included text words and relevant
indexing to capture pharmacoepidemiological studies
satisfying the inclusion criteria. The strategies were
adapted to match the structure of each database and
were based on search terms that included ‘drugs’, ‘da-
tabases’, and ‘epidemiology’/‘observational studies’
(using MeSH, Emtree, and free text terms); both data-
bases were searched from 2007 to October 2013 (see
e-tables 1 and 2 for the full search strategy in Pubmed
and Embase, respectively). The date ﬁlter from 2007
onwards was applied as our pilot searches did not
identify any relevant publications before 2007. We
therefore believed that it would help improve the pre-
cision of the search without negative impact on its sen-
sitivity. One author (IE) screened the titles and
abstracts of the identiﬁed articles using our inclusion
and exclusion criteria to select articles eligible for
full-text screening.
The electronic literature search was supplemented
with a manual search (2007 to December 2013). We
identiﬁed publications listed on the following research
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projects’ websites: (i) OMOP (http://omop.fnih.org
and www.omop.org); (ii) Mini-Sentinel (www.mini-
sentinel.org); (iii) the HMO Research Network
(www.hmoresearchnetwork.org); (iv) EU-ADR (www.
euadr-project.org); (v) IMI-PROTECT (www.imi-pro-
tect.eu); (vi) AsPEN (www.aspennet.asia); and (vii)
CNODES (www.cnodes.ca). In addition, researchers
within our team were consulted to add multi-
database projects that they were aware of (and that
were not identiﬁed in the automatic and website
searches). The titles and abstracts were screened to
determine which articles were eligible for full-text
screening.
Two authors (IE and MB) reviewed the full-text of
all potentially relevant studies to determine ﬁnal
inclusion.
Data extraction process
A data extraction form was designed to extract rele-
vant data from the selected studies. Data extraction
was ﬁrst performed by one reviewer (MB) with subse-
quent quality assurance performed by the second re-
viewer (IE). Disagreements were resolved through
discussion with a third reviewer (MA).
Analysis of study characteristics
We retrieved information about the objective of the
studies, the exposure, the outcome, the study design,
and the number of different databases and countries.
Further, we classiﬁed studies according to the methods
that were used for individual-level analyses and meta-
analyses. Regarding the meta-analyses, we deﬁned
three different levels of combining data:
(1) An aggregate level approach, in which separate
analyses are performed on datasets from each
database and overall results (adjusted effect
estimates with conﬁdence intervals) are collected
for meta-analysis. The analyses are usually
‘database-optimized’ in the sense that the best
available data for each database are being used.
This approach allows using the normal statistical
techniques for meta-analysis, including random-
effects models, to account for heterogeneity of
study results. Further, meta-regression can be used
for assessing variation in effects related to covari-
ates, which may explain some of the overall
heterogeneity.
(2) A semi-aggregate level approach, in which strati-
ﬁed datasets with event counts (and for cohort
studies person time) are collected from all data-
bases for one common analysis (e.g. a distributed
data network). Datasets can be stratiﬁed on out-
come, exposure, and covariate patterns (age, sex,
time since initiation, and selected confounders).
For a cohort study, this approach employs a
Poisson regression model on tables of event num-
bers and person time stratiﬁed by exposure and
covariate patterns. For a case–control study, a lo-
gistic regression model can similarly be used to
analyze frequency tables of cases and controls
stratiﬁed by different covariates.
(3) An individual level approach, in which individual
patient data are collected from all databases for
one common analysis. In this scenario, the infor-
mation from different databases has to be made
compatible with regard to deﬁnitions of expo-
sures, outcomes, covariates, and time windows.
Heterogeneity of study populations and variation
in the effects both of exposure and covariates be-
tween databases may affect the results. This may
be accounted for using statistical techniques
correcting for overall variation within and be-
tween databases.
With regard to data management, we were interested
in which data were collected centrally and whether
central programming or the use of distributed common
programs was mentioned in the article. Moreover,
motivations for conducting the study (as stated in
the article) were classiﬁed. For all questions there
was a category ‘not speciﬁed’ that could be ticked.
This category is only shown in the result tables if there
was at least one study with missing data. Frequen-
cies were calculated to describe the study character-
istics, data analysis techniques, data management,
and motivations.
RESULTS
The PubMed and Embase searches identiﬁed 3083
publications (see Figure 1). After the screening of ti-
tles and abstracts, 44 articles were selected for a full-
text screening. The manual search identiﬁed an addi-
tional 176 publications; 22 from OMOP, 64 from
Mini-Sentinel, 34 from the HMO Research Network
(based on a Pubmed search, because no articles were
found on the project’s website), 36 from EU-ADR,
11 from IMI-PROTECT, 2 from AsPEN, 2 from
CNODES, and 5 from individual projects (data not
shown in the ﬂowchart). After review of titles and ab-
stracts we selected 31 articles for a full-text screening.
Figure 1 shows that from the 75 articles selected for
full-text screening, 22 were ﬁnally selected for
inclusion.
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E-table 3 gives an overview of the 22 studies in-
cluded in our review.9–30 Six studies were published
between 2007 and 2010, while a majority of 16 studies
was published between 2011 and 2013. For seven
studies, there was a method objective in addition to
an overall (mostly clinical) objective.10,13,15,17,18,23,27
Figure 2 shows which countries contributed to the
multi-database projects. From the 22 studies, there
were 14 (64%) that used at least one database from
the U.S. or Canada. Half of the studies (50%) used at
least one European database. Within Europe, data
from Great Britain were most often used: there were
nine studies (41%) that used a British database (with
the Clinical Practice Research Datalink (CPRD) being
the most frequently used one, i.e. ﬁve times). Further,
there were ﬁve studies that used at least one
Scandinavian database (23%), ﬁve studies that used a
database from the Netherlands (23%), and ﬁve studies
that used an Italian database (23%).
Table 1 shows that most studies addressed safety
(82%) rather than effectiveness issues (23%). The de-
sign that was most often used was the cohort study de-
sign (82%) as opposed to the case–control design
(18%). The number of databases used per study ranged
from 2 to 17 (median=4.0), while the number of coun-
tries involved ranged from 1 to 6 (median=2.5). The
type of exposure that was most frequently studied
was medication related to the nervous system (41%),
for example antidepressants and dopamine agonists.
In terms of outcomes, cardiac disorders were most fre-
quently represented (36%), followed by all-cause mor-
tality (23%) and nervous system disorders (18%). The
Figure 1. Flowchart of the selection of articles. * No papers were excluded because they were non-English (there were 122 non-English papers but they were
excluded because of other exclusion criteria)
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code system used to identify exposure was often not
speciﬁed (82%), while for the outcome this was less
often the case (18%).
Table 2 shows that logistic regression was most fre-
quently used for individual-level analyses (41%),
followed by Cox regression (23%) and Poisson regres-
sion (14%). As meta-analysis method, a majority of
the studies used an individual level approach (73%)
(see e-table 4 for the exact categorization). There were
three studies with a semi-aggregate approach (14%),
and six studies performed an aggregate meta-analysis
(27%). For two studies, the aggregate meta-analysis
was the only meta-analysis that was conducted (be-
cause data were collected on an aggregate level). The
other four aggregate meta-analyses were conducted in
addition to an individual patient data meta-analysis (three
studies) or a semi-aggregate meta-analysis (one study).
There were four studies that collected semi-aggregate
datasets (18%), but one of them did not use this
information in a meta-analysis (reﬂected in the category
‘meta-analysis: none’). A quantitative heterogeneity as-
sessment was conducted in almost half of the studies
(45%) without one speciﬁc test being most popular.
For 12 studies, central programming was mentioned
in the publication. The use of distributed common
programs was mentioned for ﬁve studies; in three
cases these common programs were used in a semi-
aggregate level approach, and the other two cases were
related to an aggregate level approach.
Amajority of the articles motivated their multi-database
study by power or mentioned power as a strength of their
study (86%) (data not shown in a table). Only one article
explicitly mentioned rare exposure as an argument, and
three articles made mention of a rare outcome. External
validity was stressed in six publications (27%), while only
three articles mentioned comparing different populations
or databases as an argument to perform a multi-database
project (14%).
Figure 2. Map of countries involved in multi-database studies. Legend: - the numbers reﬂect how many times the country (at least one database) was in-
volved in a multi-database study (the darker the color, the higher the number of studies) - stripes: country not involved in any multi-database study
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DISCUSSION
Our systematic literature search identiﬁed 22
pharmacoepidemiological multi-database studies, in
which data were combined for a pre-planned common
analysis or quantitative synthesis. For individual-level
analyses, logistic regression was most frequently used,
followed by Cox and Poisson regression. For meta-
analyses, 16 studies combined individual patient data,
while a semi-aggregate level analysis was conducted
in three studies and an aggregate level analysis in six.
It was a challenge to capture multi-database obser-
vational studies in a systematic literature search. Usu-
ally, the clinical topic was well represented in search
terms or keywords, but the use of more than one inde-
pendent database was much harder to capture. There is
a Mesh term called ‘Multicenter study’, but this was
on the one hand too broad (e.g. also involving studies
that selected their patients from two different hospitals,
which was not the deﬁnition of multi-database study
we were looking for) and on the other hand missing
out on relevant articles. Among studies that used more
than one database, it was almost impossible to distin-
guish studies with pooled estimates from studies that
only showed results from the separate databases, using
search terms. Because of these issues, we were quite
liberal in deﬁning the search strategy and manually
screened over 3000 articles, which only resulted in
44 articles that were selected of a full-text screening.
Still, we missed out on 31 articles that were found in
the additional manual search.
Among the studies ﬁnally selected for inclusion, the
range of different exposures and outcomes was quite
broad. This indicates that the upcoming trend of
performing multi-database observational studies stretches
out over the entire ﬁeld of pharmacoepidemiology.
Approximately half of our selected studies used at
least one database from the U.S. or Canada, and this
percentage was similar for European databases. This
indicates that Northern America and Europe currently
take an almost equal part in contributing to this rela-
tively new ﬁeld of multi-database research.
Regarding the methods of performing such a study,
we found that the combination of individual patient
data was the most frequently used technique. It should
however be noted that one of our inclusion criteria was
that data were combined for a pre-planned common
analysis. Thereby we excluded all ‘standard’ meta-
analyses that pool estimates from different studies to-
gether on a post-hoc basis, i.e. the approach of com-
bining results from published literature. This latter
type of meta-analysis is frequently used in the ﬁeld
of clinical trials and is probably also quite common
Table 1. Objective, design, exposure, and outcome
Number of studies
(total: n = 22) %
Objective category
Evidence generation 20 91%
Method / feasibility study 1 5%
Dual purpose (combination of the above) 1 5%
Study type (a)
Safety 18 82%
Effectiveness 5 23%
Design category
Cohort study 18 82%
Case–control study 4 18%
Number of databases
Range [2,17]
Mean 5.9
Median 4.0
Number of countries
Range [1,6]
Mean 2.4
Median 2.5
Drug exposure: ATC category
N—Nervous system 9 41%
A—Alimentary tract and metabolism 4 18%
C—Cardiovascular system 3 14%
M—Musculo-skeletal system 3 14%
B—Blood and blood forming organs 1 5%
R—Respiratory system 1 5%
S—Sensory organs 1 5%
Outcome: All-cause mortality/MedDRA SOC (a)
Cardiac disorders 8 36%
All-cause mortality 5 23%
Nervous system disorders 4 18%
Congenital, familial and genetic disorders 3 14%
Gastrointestinal disorders 2 9%
Musculoskeletal and connective tissue
disorders
2 9%
Blood and lymphatic system disorders 1 5%
Eye disorders 1 5%
Infections and infestations 1 5%
Pregnancy, puerperium, and perinatal
conditions
1 5%
Renal and urinary disorders 1 5%
Respiratory, thoracic and mediastinal
disorders
1 5%
Skin and subcutaneous tissue disorders 1 5%
Drug code systems (a)
ATC 4 18%
BNF 2 9%
Not speciﬁed 18 82%
Outcome code systems (a)
ICD-9 13 59%
ICD-10 8 36%
ICPC 2 9%
RCD 2 9%
CCP 1 5%
CPT 1 5%
mRS 1 5%
Not speciﬁed 4 18%
(a) One study could contribute to more than one category.
Abbreviations: ATC, Anatomical Therapeutic Chemical; BNF, British Na-
tional Formulary; CCP, Canadian Classiﬁcation of Diagnostic, Therapeutic
and Surgical Procedures; CPT, Current Procedural Terminology; ICD-9,
International Classiﬁcation of Diseases—9th revision; ICD-10, Interna-
tional Classiﬁcation of Diseases—10th revision; ICPC, International Clas-
siﬁcation of Primary Care; mRS, modiﬁed Rankin Scale; RCD, READ
CODE Classiﬁcation; SOC, system organ class.
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in the ﬁeld of observational studies, as it can be done
relatively quickly without the need of getting access
to patient-level healthcare data. If this type of meta-
analysis would have been included in our review, the
proportion of aggregate meta-analyses would therefore
have been much higher.
There were three studies that compared an individ-
ual level meta-analysis to an aggregate level (ﬁxed or
random effect) meta-analysis, using the same
data.10,13,18 In all three cases, the results were similar
between the two approaches. Importantly, these
aggregate level analyses were designed with a pre-
speciﬁed common analysis plan, i.e. the same plan as
was used for the individual level analyses, but now
without combining the individual patient data but
pooling database-speciﬁc estimates together. From a
logistic point of view, this type of aggregate meta-
analysis could be an interesting alternative to an indi-
vidual level approach, as no individual patient data
have to be transferred. Other methods that do not re-
quire sharing of individual patient data involve a dis-
tributed network approach such as the EU-ADR15 or
a case-centered logistic regression approach as de-
scribed by Toh and coworkers.27,31
It was not always clearly stated in the articles how
the data were combined. Especially the technique of
combining individual patient data (instead of combin-
ing semi-aggregate or aggregate data) was not always
explicitly mentioned. Most of the articles clearly had
a clinical focus, and descriptions of data management
were often very short or completely missing. Central
programming was mentioned for 12 studies, but the
actual number of studies that did so is probably higher,
because this technique is very likely for the studies
that combined individual patient data (16 in total).
However, the use of distributed common programs
was frequently mentioned for semi-aggregate and ag-
gregate level approaches. This is a good practice, be-
cause different ways of statistical programming may
lead to heterogeneity between results from different
databases. In the individual level approach, it was of-
ten not clearly described if and how deﬁnitions were
kept similar between data from different sources.
Power was the most stated reason for performing a
multi-database study. Comparing different populations
or databases was seldom mentioned. Many papers, es-
pecially the individual patient data studies, did not
show any characteristics of patients from the separate
databases. Overall, only half of the studies performed
a quantitative heterogeneity assessment.
There are important strengths and limitations to this
review. To our knowledge, we were the ﬁrst to per-
form a systematic literature search about methods used
in multi-database studies. Full-text screening was per-
formed by two independent reviewers, and data extrac-
tion was quality checked by a second reviewer as well.
Even though we performed a systematic literature
search, we probably missed relevant articles, because
the formulation of a suitable search strategy was not
straightforward. Our searches were limited from
2007 onwards; however, in our pilot searches with
no date ﬁlter applied we were not able to identify
any studies published prior to 2007 that would poten-
tially ﬁt our inclusion and exclusion criteria.
Table 2. Data analysis techniques and data management
Number of studies
(total: n = 22) %
Individual-level analyses
Logistic regression 9 41%
Cox proportional hazards model 5 23%
Poisson regression 3 14%
Incidence rate / incidence rate ratio 2 9%
Prevalence / prevalence ratio 1 5%
Relative risk 1 5%
Generalized linear model regression 1 5%
Exposure–time relation
Time-dependent exposure 14 64%
Intention to treat (ever / never) 7 32%
Cumulative exposure (dose or time) 1 5%
Confounder control
Conventional 11 50%
Propensity score 7 32%
Disease risk score 1 5%
None 3 14%
Meta-analysis method (a)
Individual 16 73%
Semi-aggregate 3 14%
Aggregate 6 27%
Fixed effect 4 18%
Fixed effect / random effect 2 9%
None 1 5%
Heterogeneity assessment
Quantitative test 10 45%
I-squared 2 9%
Chi-squared 1 5%
Cochran’s Q statistic 1 5%
Interaction by data source 1 5%
Kaplan–Meier stratiﬁed by database 1 5%
Not speciﬁed 4 18%
Qualitative statements only 1 5%
Not speciﬁed 11 50%
Programming
Central (leading center) 12 55%
Decentral 0 0%
Not speciﬁed 10 45%
Data collected centrally
Individual-based register data 16 73%
Semi-aggregate datasets 4 18%
Aggregate results 2 9%
Distributed common programs
Yes 5 23%
Not speciﬁed 17 77%
(a) One study could contribute to more than one category.
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Classiﬁcation into the different levels of data combin-
ing was done to the reviewers’ best effort, but was
sometimes based on very little information. Classiﬁca-
tion of motivations to perform the study may have
been susceptible to subjective interpretation.
In conclusion, multi-database studies are becoming
more popular in observational research. We feel that
there is room for improvement in making clear to the
reader how data from different databases were com-
bined; on an individual, semi-aggregate, or aggregate
level. For all scenarios, it is useful to know how deﬁ-
nitions of exposures, outcomes, confounders, and
time-windows were kept consistent across the data-
bases. Further, it should be explained how data man-
agement was organized, which data were collected
centrally and whether central programming or distrib-
uted common programs were used. It is useful to show
characteristics of patients from the separate databases
to enable the reader to evaluate whether there were
important differences. When combining data from
different databases, the performance of heterogeneity
assessments should become common practice. Even
if the objective of a study is clinical rather than meth-
odological, all this information enables a better inter-
pretation of the results of a multi-database study.
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KEY POINTS
• The upcoming trend of performing multi-
database observational studies stretches out over
the entire ﬁeld of pharmacoepidemiology.
• Regarding the methods of performing such a study,
we found that the combination of individual patient
data was the most frequently used technique.
• There is room for improvement in making clear to
readers how data from different databases were
combined (on an individual level or aggregate
level), how data management was organized, and
whether central programming was used.
• It is useful to show characteristics of patients
from the separate databases and the performance
of heterogeneity assessments should become
common practice.
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SUPPORTING INFORMATION
Additional supporting information may be found in
the online version of this article at the publisher’s
web site.
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